These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 33288659)

  • 1. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
    Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
    Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
    Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
    Wang Y; Tan K; Hu W; Hou Y; Yang G
    Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
    Zhao Y; Zhang YN; Wang KT; Chen L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
    Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
    Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
    Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of Lenvatinib in Hepatocellular Carcinoma.
    Guo J; Zhao J; Xu Q; Huang D
    Curr Cancer Drug Targets; 2022; 22(11):865-878. PubMed ID: 36267045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib: A Review in Hepatocellular Carcinoma.
    Al-Salama ZT; Syed YY; Scott LJ
    Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.